By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Interleukin Genetics today said that it has received commitments from certain institutional investors to purchase $5.3 million of the firm's stock through a direct placement.
Registering provides access to this and other free content.
Already have an account?Login Now.
In Science this week: factors influencing retrotransposon integration sites, and more.
A bioethicist argues for the responsible use of germline gene editing.
Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.
Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.